Iov-Lun-202- A Phase 2 Multicenter Study Of Autologous Tumor Infiltrating Lymphocytes (Ln-145) In Patients With Metastatic Non-Small-Cell Lung Cancer
Posted Date: Apr 28, 2021
- Investigator: Jennifer Leddon
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC using objective response rate.
Criteria:
Confirmed Histologic Diagnosis Of Non-Small-Cell Lung Carcinoma, At Least 1 Resectable Lesion. Previously Irradiated Lesion Must Have Radiographic Progression Prior To Harvest, Ecog 0-1, No Prior Malignancy Within 3 Years, No Symptomatic And/Or Untreated Brain Metastases, No Primary Immunodeficiency, No History Of Organ Transplant In 20 Years
Keywords:
Lung Cancer, Nsclc
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com